Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Cells and Professor of Universities – Hospital Practitioner at Montpellier University Hospital, shared a post on LinkedIn:
“I recently had the opportunity to be interviewed live on France 3 ICIHérault to discuss one of the most urgent challenges in oncology: the Early Detection of Pancreatic Cancer.
In this interview, we explore:
What is Liquid Biopsy?
A simple blood test that can detect tumor-derived material circulating in the bloodstream.
How can Artificial
Intelligence help medicine?
AI allows us to integrate and analyze the massive amount of biological data generated from blood samples in order to identify a specific blood signature of disease.
Our ultimate Goal:
“Detect pancreatic ductal adenocarcinoma (PDAC) at a very early stage, when treatment can still make a major difference”.
This work is part of a large French research program that I have the privilege to coordinate, supported by Fondation ARC pour la recherche sur le cancer and Les Fonds.
- François Dupré, Fabien Calvo, Nancy Abou-Zeid, Jennifer Palomo, Linda Ramdani, Sophie Wijkhuisen
- Team Effort at the national level with PANLIPSY but also at the EU level with PANCAID!
Early detection could change the story of pancreatic cancer – and liquid biopsy combined with AI may be one of the keys.
Watch the interview in the video below
Virginie Vignes, a great Journalist!
I would be delighted to hear your thoughts.”
Other articles featuring Catherine Alix-Panabières on OncoDaily.